SMARCD2 and neuroblastoma: With 10 nM sGD2, the decrease of NAXI binding was significant at mAb concentrations ranging from 0.001 to 0.1 μg/mL with no effect on DB binding, indicating that low sGD2 levels also impact NAXI binding to GD2-expressing neuroblastoma cells.